HiberCell Revenue and Competitors
Estimated Revenue & Valuation
- HiberCell's estimated annual revenue is currently $4.6M per year.
- HiberCell's estimated revenue per employee is $77,500
- HiberCell's total funding is $158.2M.
Employee Data
- HiberCell has 59 Employees.
- HiberCell grew their employee count by -3% last year.
HiberCell's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder, President & CEO | Reveal Email/Phone |
2 | VP Preclinical Pharmacology | Reveal Email/Phone |
3 | VP Technical Operations | Reveal Email/Phone |
4 | VP, Medicinal Chemistry / Drug Discovery | Reveal Email/Phone |
5 | VP Clinical Operations and Program Management | Reveal Email/Phone |
6 | VP, Head Regulatory Affairs | Reveal Email/Phone |
7 | Associate Director Finance | Reveal Email/Phone |
8 | Executive Assistant & Officer Manager | Reveal Email/Phone |
9 | Executive Director - Analytical Development | Reveal Email/Phone |
10 | Associate Director In Vitro Translational Oncology | Reveal Email/Phone |
HiberCell Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.3M | 92 | 100% | N/A | N/A |
What Is HiberCell?
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As ￃﾢ￢ﾂﾬￅﾓthe dormancy company,ￃﾢ￢ﾂﾬￂﾝ we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
keywords:N/A
$158.2M
Total Funding
59
Number of Employees
$4.6M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
HiberCell News
HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m. Concurrent to this financing, the company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE ...
Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced that it has ...
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointments of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D., to its scientific advisory b ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.3M | 59 | 18% | N/A |
#2 | $13M | 59 | 9% | $2M |
#3 | $11.7M | 59 | 0% | $15M |
#4 | $7.5M | 59 | -8% | N/A |
#5 | $14.3M | 59 | -6% | N/A |